Prostatype®– a new gene test for prostate cancer patients
Laboratories & Universities
The strategy and business idea is to market and sell in the global market a complete diagnostic system consisting of reagents for testing and quality assurance and evaluation software, adapted to the instrumentation platforms of leading Molecular Diagnostics companies. We strive to develop and produce frontline product solutions designed for optimal user compliance as well as fulfillment of the highest quality demands. Our product, the Prostatype® Test System, will meet an urgent medical need and have a positive impact on the overall health economy as well as preserve the quality of life for thousands of men each year.
The company also partners with leading diagnostic companies to develop products and services; for the market.
Aleris / MediLab AB
Commercial lab in Täby analysing 1200 biopsy tests per year, test site during development. Large bank of formalin fixed paraffin embedded tumor material avaliable for Chundsell Medicals development work.
Universitäts Spital Zürich
Institut für Klinishe Pathologie, Wild Lab. Systems pathology and high-throughput genomics laboratory.
Epigenomics AG, Berlin, Contractual Developer with own qPCR tests on the market
DAKO A/S, Copenhagen, Development collaborator Immunohistochemistry
Roche Diagnostics, Sweden, Germany & Switzerland
S&M Cooperation Instrumentation (Sweden)
Roche Diagnostics Deutschland GmbH (Germany)
Roche Diagnostics AG (Switzerland)
Business Incubator (STING), Kista, Sweden
HISTO-CENTER AB, Gothenburg, Sweden
If Skadeförsäkringar, Stockholm, Sweden
Research and development, production and sales of the Prostatype Test System is insured for the Nordic countries by our partner IF.